Abstract

Background: Long-term administration of low-dose aspirin (LDA) is associated with greater risk of adverse events, including gastro duodenal ulcers. This study aimed to assess the risk factors and efficacy of medications to prevent the development of peptic ulcer disease in Japanese patients without prior history of peptic ulceration. Methods: We conducted a matched case-control study using esophagogastroduodenoscopy records collected from January through December 2010. We enrolled 219 consecutive outpatients receiving LDA (100 mg) and 219 ageand sex-matched controls who did not receive LDA and did not have a prior history of peptic ulcer. Clinical parameters, reason for endoscopy, and endoscopic findings were analyzed. Results: A significantly higher number of patients receiving LDA compared to those not receiving LDA were diagnosed endoscopically with peptic ulceration (20 [9.1%] vs. 7 [3.2%]; odds ratio [OR], 3.0; 95% confidence interval [CI], 1.26−7.35; p=0.016). Multiple logistic regression analysis identified male sex, abdominal symptoms, and non-steroidal anti-inflammatory drug (NSAID) and LDA use and PPI use as risk and protective factors, respectively, for peptic ulcer (OR, 4.7, 95% CI, 1.28−17.64, p=0.020; OR, 2.5, 95% CI, 1.01−6.12, p=0.047; OR, 6.8, 95% CI, 1.72−26.40, p=0.006; OR, 9.72; 95% CI, 2.64−35.72, p=0.006; and OR, 0.1, 95% CI, 0.04−0.57, p=0.006, respectively). Conclusion: LDA and NSAID use increases the risk of peptic ulcer even in patients without peptic ulcer history; proton pump inhibitors reduce the risk of developing gastric or duodenal ulcers. These results may help identify patients who require interventions for the prevention of NSAIDor LDA-induced peptic ulcers.

Highlights

  • The use of low-dose aspirin (LDA; 75−325 mg daily) contributes to the prevention of thrombi and emboli in patients with ischemic heart disease or ischemic cerebrovascular disease [1]

  • In Japan, since 2011 and 2013, treatment with half-dose pump inhibitors (PPIs) and full-dose PPI for the prevention of non-steroidal anti-inflammatory drug (NSAID)- or LDA-induced peptic ulcers, respectively, has been permitted as a medical service under health insurance for patients with a history of peptic ulcers that is associated with a high risk for the future development of peptic ulcers

  • Male sex, abdominal symptoms, NSAIDs, and LDA were identified as risk factors for peptic ulcers

Read more

Summary

Introduction

The use of low-dose aspirin (LDA; 75−325 mg daily) contributes to the prevention of thrombi and emboli in patients with ischemic heart disease or ischemic cerebrovascular disease [1]. Yeomans et al [12] stated that the use of esomeprazole 20 mg reduces the risk of developing LDA-associated gastric and/or duodenal ulcers in elderly patients without preexisting gastro duodenal ulcers. Only a few studies have reported a reduced risk of LDA-associated peptic ulcers owing to the use of PPIs in patients without preexisting peptic ulcers. The aim of this retrospective case-control study was to clarify the risk and effect of PPIs on peptic ulcer development in Japanese patients receiving LDA who did not have preexisting peptic ulcers. Long-term administration of low-dose aspirin (LDA) is associated with greater risk of adverse events, including gastro duodenal ulcers. This study aimed to assess the risk factors and efficacy of medications to prevent the development of peptic ulcer disease in Japanese patients without prior history of peptic ulceration

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call